FDA approves Boehringer drug to treat advanced lung cancer

July 12, 2013 2:30 PM

12 0

FDA approves Boehringer drug to treat advanced lung cancer

(Reuters) - The U.S. Food and Drug Administration approved a lung cancer drug made by Boehringer Ingelheim to treat patients who are suffering from late stage non-small cell lung cancer and whose tumors express a specific type of gene mutation.

The drug, Gilotrif, was approved along with a companion diagnostic kit that can help determine if a patient's lung cancer cells express the epidermal growth factor receptor (EGFR) gene mutation.

Read more

To category page

Loading...